Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive Revised Protocol 04, incorporating Protocol Amendments 02, 03, 04 and 05

Next Previous
Trial Profile

Dose-Ranging Study to Evaluate the Safety, Efficacy and Pharmacokinetics of Pegylated Interferon Lambda (BMS-914143) Monotherapy in Interferon-Naive Patients with Chronic Hepatitis B Virus Infection who are HBeAg-positive Revised Protocol 04, incorporating Protocol Amendments 02, 03, 04 and 05

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 07 Apr 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Peginterferon lambda-1a (Primary) ; Entecavir; Peginterferon alfa-2a
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
  • Acronyms LIRA-B
  • Sponsors Bristol-Myers Squibb

Most Recent Events

  • 28 Dec 2015 Results published in the Journal of Hepatology
  • 30 Jun 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
  • 13 Apr 2014 Results at 24 weeks post-treatment presented at the 49th Annual Meeting of the European Association for the Study of the Liver.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top